The impact of HIV-1 genetic diversity on candidate vaccines is uncertain. To minimize genetic diversity in the evaluation of HIV-1 vaccines, vaccine products must be matched to the predominant subtype in a vaccine cohort. To that end, full genome sequencing was used to detect and characterize HIV-1 subtypes and recombinant strains from individuals in Rakai District, Uganda. DNA extracted from peripheral blood mononuclear cells (PMBC) was PCR amplified using primers in the long terminal repeats (LTRs) to generate nearly full length genomes. Amplicons were directly sequenced with dye terminators and automated sequencers. Sequences were phylogenetically analyzed and recombinants were detected and mapped with distance scan and bootscan. Among 46 sequences, 54% were subtype D, 15% were subtype A, and 30% were recombinant. All recombinants were individually unique, and most combined subtypes A and D. Subtype D comprised more than 70% of all the HIV-1 genomes in Rakai when both pure subtypes and recombinants were considered. Candidate vaccines based on HIV-1 subtype D would be appropriate for evaluation in Rakai District, Uganda.
INTRODUCTION H
IV-1 IS GENETICAL LY DIVERSE.
1-4 A phylogenetic tree of HIV-1 sequences reveals three groups: M (main group), N (new or non-M, non-O), and O (outlier). 1, 5 Group M represents the vast majority of the infections worldwide and is divided, by phylogenetic analysis, into nine distinct subtypes (A, B, C, D, F, G, H, J, K). 1, 3, 5 Intersubtype diversity ranges from 15% of nucleotides in the structural (gag) gene to 25% in the envelope (env) gene. 1 Intrasubtype diversity ranges from 5 to 12%. 1 Genetic recombination further contributes to the diversity of HIV-1. 3, 4, 6 Recombination arises when a cell becomes coinfected with two different viruses. A plus-strand RNA from each virus can be copackaged into a new virion, and, after infection of a new cell, reverse transcription can recombine the genetic material from the two RNA strands during proviral DNA synthesis. 4 It is difficult to define the contribution of recombination within the context of the primarily HIV-1 subtype B epidemic in the United States. However, the frequency can be defined in regions of the world in which the HIV-1 epidemic has subtype diversity and intersubtype recombination occurs. A circulating recombinant form (CRF) can be identified when three or more sequences from epidemiologically unrelated individuals have recombinant viruses sharing identical recombinant structures. 1, 5 To date, 14 circulating recombinant forms have been reported (http://hiv-web.lanl.gov/).
The distribution of HIV-1 subtypes and recombinants varies geographically. [2] [3] [4] The greatest diversity of HIV-1 subtypes is observed in West Central Africa where the HIV-1 epidemic is thought to have arisen from one or more zoonotic transmissions. 2, 4, [7] [8] [9] The inferred spread of HIV-1 subtypes from West Central Africa has apparently involved a limited number of subtypes. For example, subtype B represents the vast majority of infections in the United States, Europe, and Australia and subtype C predominates in Southern Africa. 3, 4 CRFs represent the predominant viral strain in several countries. 3, 4, 10, 11 These patterns may be due to the random introduction of founder viruses. 12, 13 Differences between HIV-1 subtypes 4 or human population genetics may have played some part in the global distribution of subtypes.
The genetic diversity of HIV-1 represents one of several challenges in the path to a globally effective vaccine. There are several viruses for which vaccines have been successful that have much less genetic diversity than HIV-1. 14 It is unknown if a vaccine based on one particular sequence or even on a consensus sequence from one HIV-1 subtype will elicit an immune response sufficient to protect against infection by other subtypes or by a recombinant. There is evidence for cross-subtype recognition by both neutralizing antibodies [15] [16] [17] and cytotoxic T cell lymphocytes. [18] [19] [20] [21] Given the many hurdles for developing an HIV-1 vaccine, it is reasonable to minimize subtype diversity as a variable in the design and evaluation of novel HIV-1 vaccine candidates.
Volunteers in the Rakai district of Uganda may participate in HIV-1 vaccine evaluations in the near future. Characterization of the genetic diversity of HIV-1 in Uganda has relied primarily on partial genome analysis and has not focused on the Rakai district. 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] These analyses used sequencing and/or screening methods on subgenomic regions (env, gag, and pol) and identified subtypes A, C, D, and G. Reports indicated that subtypes A and D predominated in Uganda from the mid1980s. 29 Several studies identified intersubtype recombinant HIV-1 in Uganda often defined by analysis of two or more subgenomic regions in each strain. 25, 27, [37] [38] [39] [40] [41] However, recombination may have been underestimated with these methods because only a small fraction of the whole HIV-1 genome was examined.
Given the desirability of matching a vaccine to the prevalent subtype in Rakai, near full length genomes have been sequenced to maximize detection of recombinant viruses, fully characterize the recombinants, and determine the distribution of HIV-1 genetic subtypes and overall contribution of the various subtypes in the Rakai district. Even if recombinant viruses are common, they may reflect the predominant subtype for much of their genomes. Sequence data will help determine whether a monovalent or bivalent vaccine strategy should be evaluated in Rakai, and these sequences will be further utilized to develop the vaccine candidates.
MATERIALS AND METHODS

Cohort
Thirty-seven samples were derived from volunteers in Rakai district, Uganda enrolled into longitudinal, population-based cohort studies beginning in 1995. Participants in the current analysis were identified from the STD Control for AIDS Prevention trial (1994) (1995) (1996) (1997) (1998) (1999) 42 and from the Community HIV Epidemiological Research Study, a population-based HIV surveillance project. All volunteers provided written informed consent at each survey round. The studies were reviewed and approved by human subject ethics and safety committees in the United States (Columbia University, Johns Hopkins University, Walter Reed Army Institute of Research, NIH Office of Human Research Protection) and in Uganda (Uganda Virus Research Institute and the AIDS Research Subcommittee of the Uganda Council for Science and Technology). All participants were offered health and HIV prevention education, condoms, and voluntary HIV testing and counseling.
Of the 46 individuals whose HIV-1 strain was evaluated in these studies, 17 were prevalent cases, and 29 seroconverted during the studies. Seroconversion for these incident cases was estimated as the midpoint between the last negative and first positive HIV-1 test, which were conducted approximately every 10 months.
Materials
When a volunteer tested positive for HIV-1, whole blood was drawn at 0 and 2 months. Peripheral blood mononuclear cells (PBMC) were purified from anticoagulated whole blood using CPT (Becton Dickinson, Annapolis, MD) or ADC/Ficoll density centrifugation (Amersham Pharmacia Biotech, Piscataway, NJ). Samples 57128, 57129, 57131, 57132, 57134-57137, and 57139 (n 5 9) were anonymously collected, discard samples from a clinic in Rakai. Some samples (57128, 57130, 57143, 57147, K30889, and A07412) were cocultured with phytohemagglutinin (PHA)-stimulated donor PBMC prior to extraction. 43, 44 Sample processing and amplification Genomic DNA was extracted from PBMC, derived either from the 0 or 2 month blood draw, using Qiagen's Blood and Tissue kit (Qiagen, Inc., Valencia, CA). Near full length HIV-1 genomes were amplified with a nested polymerase chain reaction (PCR) strategy as previously described. 45, 46 Sequencing PCR amplicons were directly sequenced with the exception of samples 57128, 57129, 57131, 57136, 57137, 57139, 57140, 57142, 57143, and 57146. These amplicons were cloned into pCR-XL-TOPO using TOPO TA cloning kits (Invitrogen, San Diego, CA) or in the case of 57143 into pLTR(B) as previously described. 47 One full length clone was selected for sequencing. 57130 and 57147 were sequenced from PCR amplicons and from pCR-XL-TOPO clones. In all cases, both DNA strands were sequenced using a 1:1 mixture of Big Dye Terminator kits [Applied Biosystems (ABI), Foster City, CA] and Half Dye (Sigma-Aldrich, USA). Reactions were run on an ABI 377 sequencer or an ABI 3100 capillary sequencer. One sequence was generated for each sample. DNA sequences were assembled and edited using Sequencing Analysis (ABI) and Sequencher 3.1 (Genecodes, Ann Arbor, MI) software.
Phylogenetic analysis
Sequences were manually aligned to an existing alignment that began at the seventh nucleotide of gag and extended twothirds into nef. Gaps in the alignment were stripped prior to analysis. Phylogenetic analysis was performed using the Phylip software package. 48 Neighbor-joining trees with bootstrap (100 iterations) were built using Phylip distance methods with the Kimura two-parameter model. 49, 50 Bootstrap values greater than or equal to 70% were considered significant. 51 Distance scans using the Kimura two-parameter model were performed with 300 nucleotide windows overlapping by 50 nucleotides and a transition/transversion ratio of 2.0. 10 Bootscan analyses were performed using parsimony with 300 nucleotide windows overlapping 20 nucleotides. 49 Initially, reference sequences of subtypes A, D, C, and J were used for bootscanning. Then distance scans were used to pick the best references for bootscanning of potential recombinants. Breakpoints were estimated as the midpoint of the window where bootstrap values approached 50%.
The reference sequences used in neighbor-joining trees to confirm breakpoints included A1 (92UG037, SE8891),
, and CRF02_AG (IbNG, DJ264). 52 
Genetic distribution analysis
To interpret the overall genetic composition of major HIV-1 structural genes, gag, pol, env, the contribution to subtypes A, C, and D from each of the recombinants was calculated using the breakpoint positions in the alignment and the positions of start and stop codons for each gene. Nonrecombinant and recombinant viruses were then combined to determine the proportions of subtypes A, C, and D in all sequences for each of the major gene products that will be vaccine targets. The signal peptide of env was not included in the analysis of env. Gaps were not stripped for the analysis of genetic distribution.
Hypermutation analysis
All seven nonrecombinant subtype A sequences were analyzed by the Los Alamos Hypermut program (http://hivweb.lanl.gov/HYPERMUT/hypermut.html) to identify the presence of hypermutation. Subtype A strains 57136 and G03379 were used as reference sequences. Similarly, all 25 nonrecombinant subtype D sequences were analyzed for hypermutation using Hypermut. Subtype D strains A07412 and A03349 served as reference sequences.
RESULTS
Viral sequences were obtained from 46 HIV-1 seropositive individuals. Demographic data for these individuals and the subtype of the virus are presented in Table 1 . In this analysis, 62% of volunteers were males, and the mean age in years (6 standard deviation) was 27 (68) . The mean ages in years for females and males were 24 (67) and 29 (68) , respectively. The blood draw dates for sequencing occurred in 1998 and 1999. For the incident cases, the mean time (6 standard deviation) between seroconversion and collection of PBMC for sequencing was 17 months (66 months). Thus, the sequences represent a recent composite of the viruses in the Rakai district and include both prevalent and incident infections.
A neighbor-joining tree of the 46 sequences, along with reference sequences of subtypes A, C, and D, was generated (Fig.  1A) . Thirty-three of the sequences clustered with the subtype D reference sequences, and four of these (57139, E22831, F27390, and K38855; Fig. 1A ) formed noticeably deeper branches in the subtype D cluster. Twelve sequences clustered significantly with subtype A references, and two of these (C06443 and J21953, Fig. 1A ) have noticeably deeper branches in the cluster. Sequence B26587 was an outlier to all of these subtypes; none of the sequences shared a significant bootstrap with only subtype C references.
The deeper branches within subtypes A and D and the outlier sequence suggested that these sequences were recombinant, so all sequences were examined for the presence of recombination using bootscanning (data not shown). Fourteen of the 46 sequences were recombinant and are indicated by crosshatching in Figure 1A . Some of them clustered closely within subtype A or D, while others were either deep branches within these subtypes or were outside all three subtypes. The confirmation and structure of the recombinant strains will be described below.
To gain information about the intrasubtype diversity among the nonrecombinant strains, another neighbor-joining tree was constructed excluding the recombinant strains (Fig. 1B) . References for subtypes C, D, and A including references for the recently identified A2 subsubtype were included. The 25 subtype D sequences formed a significant cluster with references from East Africa (bootstrap value of 100%). There were seven nonrecombinant subtype A sequences. None of the sequences, identified as subtype A, clustered with references for subsubtype A2. C27305 is the most distant of these; it had an unusually long branch length. The translated protein sequences of C27305 showed many premature stop codons in its open reading frames (data not shown). Using the Hypermut program (http://hiv-web.lanl.gov/HYPERMUT/hypermut.html), 53 it was determined that C27305 had an approximately 2-fold greater number of G to A changes relative to the other subtype A sequences from Rakai (data not shown). The distribution of these G to A changes in the four GN dinucleotide contexts (where N is any nucleotide) was skewed to the GG context consistent with hypermutation. 54 In contrast, the other subtype A Rakai sequences had an almost even distribution of G to A changes in the four contexts (data not shown). No nonrecombinant subtype D strains were found to be hypermutated (data not shown). Excluding strain C27305, the mean (6 standard deviation) pairwise distances between subtype A strains (n 5 6) and between subtype D strains (n 5 25) were 0.08 (60.01) and 0.070 (60.008), respectively. In comparison, 11 full length subtype A references from Africa had a mean pairwise distances of 0.079 (60.009) and were intermingled with the Rakai subtype A sequences. Twenty-three of the 25 subtype D sequences and two references formed a significant internal cluster (bootstrap value of 100%). Sequences 57130 and 57143 and several references were outside this internal cluster (Fig. 1B) . 57130, 57143, and Ugandan reference 92UG001 were 1-2% more distant relative to the distances between the subtype D Rakai sequences in the internal cluster. However, a bootstrap (100%) clustered 57130, 57143, and 92UG001 with the other Rakai subtype D sequences. West African references formed a significant cluster (bootstrap value of 100%).
Next the recombinant strains were analyzed in detail. Distance scanning was used to identify the component subtypes and bootscanning was used to locate recombination breakpoints.
Segments of the genome were excised according to these breakpoints and analyzed by neighbor-joining with the bootstrap in alignments that contained representatives of all subtypes. Bootstrap values greater than 70% were used to assign segments to a particular subtype. The results of these analyses are shown in HARRIS ET AL. 1284 With the exception of a small region of strain 57139, all regions of the recombinants could be assigned to subtype A, C, or D. Each of the recombinants had a different structure. There were 11 AD recombinants, 2 AC recombinants, and one CD recombinant. Both AC recombinants have subtype C vpu. Among the AD recombinants, there were strains composed almost entirely of subtype A, but others were almost entirely subtype D. Two had only two crossover points while one alternated subtype 11 times across the genome. There was no obvious preferred location for breakpoints.
Of interest, there were three subtype C-containing recombinants but no nonrecombinant subtype C strains. The subtype and breakpoint structures of the recombinant strains did not match the structures of recombinants recently identified in neighboring Kenya 55 and Tanzania 56 or reported in GenBank (data not shown).
The overall proportions of subtypes and recombinants are depicted in Figure 3 . Subtype D accounted for 54%, subtype A for 15%, and recombinant strains comprised 30%. Most of the recombinants were AD, constituting 86% of the recombinants and 24% of all strains. When considering only samples from individuals with known dates of seroconversion (which were within 1997 and 1998), subtype D was 59%, subtype A was 10%, and recombinants strains were 31%.
The most prominent HIV-1 strains among this sample from Rakai were subtype D and D-containing recombinants, together constituting 80% of the strains. To further inform vaccine development, the subtype composition of major structural genes in the sample was considered. If the coding sequence for a structural gene contained one or more breakpoints in a recombinant strain, we estimated the fraction of the gene that derived from each of the subtypes. When combined with the pure subtypes, the results (Fig. 4) showed no obvious disparity among gag, pol, and env genes. Figure 4 shows the separate contributions of nonrecombinant (solid bars) and recombinant (hatched bars) strains. More than 70% of the genetic material in structural genes comes from subtype D, mostly within nonrecombinant strains. At least half of the genetic material from recombinants was subtype D. Subtype A accounts for about 30% of the genetic material, with about half from nonrecombinant and half from recombinant strains. The trace amount of subtype C material was mostly in gag and pol genes and only in recombinants in each of the three genes. unclassified. The number in each box is the bootstrap value for a cluster containing the region of interest with references of the indicated subtype (NS 5 not significant, a bootstrap less than 70%).
DISCUSSION
recombinants. In the total viral population, subtype D represents 70% or more of the genetic material in three HIV-1 genes that are candidates for inclusion in a vaccine. All but two of the nonrecombinant subtype D sequences radiate from approximately the same point and are roughly equidistant from each other. Two sequences (57130 and 57143) are outliers relative to the other Rakai subtype D sequences based on their position in a phylogenetic tree of nonrecombinant subtypes. However, these two sequences did cluster with the Rakai sequences and East African references rather than with West African subtype D references. A candidate vaccine based on subtype D, using any of the 23 equidistant subtype D sequences reported here, would be an appropriate choice for a monovalent vaccine in the Rakai district.
Subtype A is the other nonrecombinant found in Rakai, representing approximately 15% of strains. When the amount of subtype A is considered in both recombinant and nonrecombinant viruses, it comprises about 30% of the sequence coding for gag, pol, and env. Previous estimates of subtype A by partial genome analyses ranged from 20% to over 50%. [22] [23] [24] [25] [26] 29, [31] [32] [33] [34] [36] [37] [38] [39] 57, 58 The reports above sampled outside of the Rakai district, and it is possible that the proportion of subtype A varies in different parts of Uganda, 36 but underestimation of recombinants will also contribute to the differences.
Recombinants represent 30% of the viruses in Rakai. Partial genome analyses had predicted 11-28% recombinations. 25, 27, [37] [38] [39] [40] [41] Most of the estimates are low relative to our data and are likely due to the examination of only one or two small regions in the genome. Based on our data, it is likely that many of the subtype A fragments detected previously were part of recombinant viruses, especially AD recombinants. A recent study by Yirrell et al., 39 which sequenced within gag and env, estimated 28% recombinants, and 23% AD recombinants, which closely mirrors our data. Their estimates of subtype A and D also are close to our findings.
No circulating recombinant forms, or CRFs, have been de- tected in the Rakai district. The AD recombinants identified in this study are all unique varying greatly in their relative composition of subtypes A and D. The single CD recombinant is distinct from CRF10_CD found in neighboring Tanzania 59 and other known CD recombinants. The two AC recombinants are also unique.
Partial genome analyses previously identified subtypes C [24] [25] [26] 28, 29, 31, 34, 38, 39, 58 and G 24, 30, 39 in Uganda. In these analyses, subtypes C and G were found in either gag or env. Using analyses of multiple genome regions, two studies had evidence for pure subtype C strains 25, 39 and one study had evidence for a pure strain of subtype G. 39 None of our 46 full length sequences from Rakai is a pure subtype C or G, and the Los Alamos database does not have a single submission of a full length subtype C or G from Uganda. We detected subgenomic regions of subtype C, but this represents very little of the genetic material in Rakai. We found subtype C in gag, vpu, and nef but not in env as previously reported. The analysis of full length sequences did not reveal any subtype G regions except where it is not separable from subtype A. Subtype G is found primarily in Central and West Africa. 58, [60] [61] [62] If pure strains of either subtype C or G exit in Rakai, they are present at low levels.
Two countries neighboring Uganda have epidemics with the same subtypes as Rakai but in different proportions. In southern Tanzania (Myeba), the predominant subtype in nonrecombinant and recombinant viruses is C. 56 This probably reflects introduction from neighbors to the south where subtype C abounds. 45, [63] [64] [65] In Myeba, there are also nonrecombinant (22%) and recombinant subtype A and recombinant subtype D viruses. 56 Partial genome sequencing reveals subtype A and D in other regions of Tanzania. [66] [67] [68] [69] [70] [71] [72] [73] Subtype C has only recently been observed in the northern areas of Tanzania. 71 Bordering Uganda on the east, Kenya has predominantly subtype A in both nonrecombinants (55%) and recombinants based on a new study of near full length sequences. 55 Subtypes C and D occur as nonrecombinants (2% each) but to a much lesser extent than subtype A, and they are also found in recombinants. 55 A full length subtype G has been found previously from Kenya, 74 but was not found in the new report. 55 With recombinants between A1, A2, and D; A2 and D; A1 and D; A1 and G; A1 and C; A1, C, and D; and C and D, 55 Kenya has more diversity among its recombinants than those in Rakai, Uganda.
In summary, subtype D is the predominant subtype found in nonrecombinant and recombinant viruses in the Rakai district of Uganda. Despite 30% of our sequences being recombinants, 70% of the genetic material in gag, pol, and env is subtype D. Thus, a vaccine based on subtype D has the opportunity to elicit immune responses that are closely related, wholly or in part, to a large majority of viruses in Rakai. The proposed, future vaccine trials for East Africa can be a model for subtype escape and will provide insight into vaccine requirements for broadness of immunogenicity and evidence of cross-protection.
SEQUENCE DATA
The GenBank accession numbers for the 46 sequences are AF484477-AF484522 (see also Table 1 ).
